Pharvaris N.V.
↗Leiden, Netherlands / Zug, Switzerland
Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of innovative, oral therapies for rare diseases, specifically bradykinin-mediated angioedema. The company aims to provide patients with alternatives to traditional injectable therapies, focusing on injectable-like efficacy with the convenience of oral administration.
Its lead candidate, deucrictibant, is a small-molecule bradykinin B2-receptor antagonist being developed in two formulations: an immediate-release capsule for the on-demand treatment of hereditary angioedema (HAE) attacks and an extended-release tablet for the prophylactic prevention of HAE attacks. The company is also exploring the application of its technology in acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$164M (Pre-IPO)
Investors:General Atlantic, venBio Partners, Bain Capital Life Sciences, Foresite Capital, Venrock Healthcare Capital Partners, Kurma Partners, Life Sciences Partners (LSP)
STOCK
Exchange:NASDAQ
Ticker:PHVS
Market Cap:$1.2B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule
Active Trials:4
Trial Phases:Phase 3: 4
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Challenger
Competitors:Takeda, BioCryst Pharmaceuticals, CSL Behring, Ionis Pharmaceuticals
LEADERSHIP
Key Executives:
Berndt Modig - CEO & Co-Founder
Peng Lu - Chief Medical Officer
David Nassif - Chief Financial Officer
Scientific Founders:Berndt Modig
Board Members:David Meeker, Hans Schikan, Robert Glassman, Elisabeth Björk, Viviane Monges
LINKS
Website:pharvaris.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Pharvaris N.V. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Pharvaris N.V.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.